Skip to content
Search AI Powered

Latest Stories

Elsevier unveiled PharmaPendium: a drug development decision-making platform

The new drug research initiative provides preclinical and clinical data that enable researchers to make informed decisions regarding drug enhancement

The global company in information and data analytics, Elsevier launched a platform, PharmaPendium for drug candidates.


It is an effective tool that provides data including complete Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval packages for drug development.

The platform is supported by the FDA, the Medical Devices Agency (PMDA) and the top 20 global pharma companies.

Olivier Barberan, Director of Translational Medicine Solutions spoke about how “improved access to highly relevant data plus predictive tools enhances regulatory success, safeguarding the massive investments of pharma companies.”

“Translation of preclinical research findings to humans in an efficient but safe way is one of the greatest challenges facing drug developers. We designed the new PharmaPendium to solve this,” he added.

“The platform leverages Elsevier’s expertise in curating scientific data and presents it in an intuitive and meaningful way for pharma professionals.”

PharmaPendium enables pharmaceutical professionals to prioritize safety and develop effective strategies for regulatory submissions.

It also offers advanced predictive tools such as the Drug-Drug Interaction Risk Calculator (DDIRC) and the Safety Margin Tool.

Moreover, they assist in optimising nonclinical studies and reducing the need for animal testing.

It helps to overcome various challenges from enhanced visualisation tools to intelligent autocomplete which increases discoverability and identifies important concepts.

The platform also offers an enhanced search interface for quick access to critical data, including drug metabolism and pharmacokinetics (DMPK), and chemistry information extracted from leading sources like complete FDA and EMA approval packages and FDA advisory committee documents.

More For You

New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less